Bipolar disorder (BD) is a psychotic mood disorder. Like schizophrenia, it has been shown to be associated with significant degeneration and structural brain abnormalities with multiple relapses.¹ ²

Just as I have always advocated preventing recurrences in schizophrenia by using long-acting injectable (LAI) antipsychotic formulations immediately after the first episode to prevent psychotic relapses and progressive brain damage,³ I strongly recommend using LAIs right after hospital discharge from the first manic episode. It is the most rational management approach for bipolar mania given the grave consequences of multiple episodes, which are so common in this psychotic mood disorder due to poor medication adherence.

In contrast to the depressive episodes of BD I, where patients have insight into their depression and seek psychiatric treatment, during a manic episode patients often have no insight (anosognosia) that they suffer from a serious brain disorder, and refuse treatment.⁴ In addition, young patients with BD I frequently discontinue their oral mood stabilizer or second-generation antipsychotic (which are approved for mania) because they miss the blissful euphoria and the buoyant physical and mental energy of their manic episodes. They are completely oblivious to (and uninformed about) the grave neurobiological damage of further manic episodes, which can condemn them to clinical, functional, and cognitive deterioration. These patients are also likely to become treatment-resistant, which has been labeled as “the malignant transformation of bipolar disorder.”⁵

The evidence for progressive brain tissue loss, clinical deterioration, functional decline, and treatment resistance is abundant.⁶ I was the lead investigator of the first study to report ventricular dilatation (which is a proxy for cortical atrophy) in bipolar mania,⁷ a discovery that was subsequently replicated by 2 dozen researchers. This was followed by numerous neuroimaging studies reporting a loss of volume across multiple brain regions, including the frontal lobe,
From the Editor

Researchers found that BD is heterogeneous with 4 stages (Table 1), and patients experience progressively worse brain structure and function with each stage. Many patients with bipolar mania end up with poor clinical and functional outcomes, even when they respond well to initial treatment with lithium, anticonvulsant mood stabilizers, or second-generation antipsychotics. With their intentional nonadherence to oral medications leading to multiple recurrent relapses, these patients are at serious risk for neuroprogression and brain atrophic changes driven by multiple factors: inflammatory cytokines, increased cortical steroids, decreased neurotrophins, deceased neurogenesis, increased oxidative stress, and mitochondrial energy dysfunction. The consequences include progressive shortening of the interval between episodes with every relapse and loss of responsiveness to pharmacotherapy as the illness progresses. 

Biomarkers have been reported in both the early and late stages of BD (Table 2) as well as in postmortem studies (Table 3). They reflect the progressive neurodegenerative nature of recurrent BD I episodes as the disorder moves to the advanced stages. I summarize these stages in Table 1 and Table 2 for the benefit of psychiatric clinicians who do not have access to the neuroscience journals where such findings are usually published.

BD I is also believed to be associated with accelerated aging and an increased risk for dementia or cognitive deterioration. There is also an emerging hypothesis that neuroprogression and treatment resistance in BD is frequently associated with insulin resistance, peripheral inflammation, and blood-brain barrier permeability dysfunction.

The bottom line is that like patients with schizophrenia, where relapses lead to devastating consequences, those with BD are at a similar high risk for neuroprogression, which includes atrophy in several brain regions, treatment resistance, and functional disability. This underscores the urgency for implementing LAI therapy early in the illness, when the first manic episode (Stage 2) emerges after the prodrome (Stage 1). This is the best strategy to

---

**Table 2**

Biomarkers of neuroprogression in early- and late-stage bipolar disorder

<table>
<thead>
<tr>
<th>Type of biomarker</th>
<th>Early bipolar disorder</th>
<th>Late bipolar disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrophins</td>
<td>—</td>
<td>↓BDNF</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>↑IL-6, IL-10, TNF-alpha</td>
<td>—</td>
</tr>
<tr>
<td>Oxidative stress (free radicals)</td>
<td>↑ 3-nitrotyrosine</td>
<td>↑Glutathione reductase, glutathione s-transferase, nitrotyrosine, TBARS, nitric oxide, lactate, total oxidants</td>
</tr>
<tr>
<td>Telomere</td>
<td>—</td>
<td>Shorter</td>
</tr>
<tr>
<td>Metals</td>
<td>—</td>
<td>↓Zinc</td>
</tr>
</tbody>
</table>

BDNF: brain–derived neurotrophic factor; IL: interleukin; TBARS: thiobarbituric acid reactive substances; TNF: tumor necrosis factor

Source: Reference 12

---

Continued on page 54
Preserve brain health in persons with BD and to allow them to remain functional with their many intellectual gifts, such as eloquence, poetry, artistic talents, humor, and social skills. It is unfortunate that the combination of patients’ and clinicians’ reluctance to use an LAI early in the illness dooms many patients with BD to a potentially avoidable malignant outcome.

Henry A. Nasrallah, MD, DLFAPA
Editor-in-Chief

References